Novartis Diebetes Drug Gets FDA Setback
14th Nov 2006, 13:24 GMT
submits: As you’ll read in Therapeutics Daily and elsewhere, Novartis reported the delay of FDA’s review of Galvus, its answer to Merck’s recently approved Januvia, by 3 months.
Novartis Diebetes Drug Gets FDA Setback related news:
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
- Novartis diabetes drug delayed — FT.com - Companies
Latest news from StratWire - Business of Healthcare NewsFeed:
- Alliance Names New COO
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud
- More Than 2 mln Cancer Patients Treated with BrainLAB m3 Shaped Beam Radiosurgery
- PA's Continuing Trend Towards Total Body Reconstruction Keeps Consumers Demanding Comprehensive Direct-To-Consumer-Education (DTCE )
- Dr Farzad Yaghouti of Global Laser Vision San Diego Wins 'Best Lasik Surgeon 2006'
- 1st Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Medical Mutual of OH Financial Investigator Wins Top Nat'l Fraud-Fighting Award
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement
- M-CARE's Medicaid Plan Recognized as One of the Top Health Plans by US News & World Report/NCQA
- Fitch: MCH rates 'A-' on bonds